Phathom Pharmaceuticals (PHAT) said Wednesday it has filed a Citizen Petition with the US Food and Drug Administration to request a 10-year New Chemical Entity exclusivity period ending May 3, 2032, for Voquezna (vonoprazan) tablets in the Orange Book listings.
The Orange Book is the common name for the organization's Approved Drug Products with Therapeutic Equivalence Evaluations publication, according to the FDA website.
The company said the exclusivity period, granted under the Generating Antibiotic Incentives Now Act for other vonoprazan-based products approved in 2022, should also apply to VOQUEZNA tablets.
The New Chemical Entity protection prohibits generic competition during the exclusivity period and aligns with legal and regulatory precedents, Phathom said.
The company also said it expects the FDA to respond to the petition within 180 days.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。